Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
Lenacapavir will be available at low cost in 120 poor countries. But nearly all of Latin America was excluded from a deal ...
The twice-yearly HIV prevention shot developed by Gilead has shown impressive results in preventing infections among both men ...
A new HIV prevention drug, lenacapavir, has shown 100% effectiveness in women and near-perfect results in men during trials.
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
Cebu Daily News on MSN13h
Twice-yearly shot could help end AIDS – drugmakerIt’s been called the closest the world has ever come to a vaccine against AIDS. The twice-yearly shot was 100% effective in ...
A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation’s ...
The adjustment comes ahead of Gilead's HIV Analyst Event, anticipated in early December, which is expected to shed light on the company's earlier-stage treatment portfolio and the commercial ...
Gilead's plan involves laying off five VPs ... for six potential new launches by the end of 2030 beginning with lenacapavir for HIV prevention in 2025," she added. The round of 100-plus cuts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback